Table 1.
Demographic and clinical details of patients with thyroid autoimmunity and control subjects without autoimmune disease
| Clinical parameter | Graves’ ophthalmopathy group | Graves’ hyperthyroidism group | Hashimoto’s thyroiditis group |
|---|---|---|---|
| Patients, n (%*) | 74 (18%*) | 131 (32%*) | 92 (23%*) |
| Age (years) | 52.4±14.6 | 48.7±15.8 | 51.8±15.3 |
| Age at diagnosis | 43±14 (n=66) | 40±16 (n=116) | 39±17 (n=99) |
| Other autoimmune disorders | 7 (41%) | 11 (7%) | 17 (15%) |
| Family history of thyroid disorders | 24 (66%) | 77 (54%) | 57 (56%) |
| Isotope scan | 21 (40%) | 52 (71%) | Not available |
| Goiter diffuse with 1–3 nodules | 23 (38%) | 29 (47%) | Not available |
| 1 nodule | 10 (29%) | 19 (27%) | 49 (47%) |
| 2 nodules | 15 (44%) | 39 (56%) | 55 (53%) |
| Medication | 51 (60%) | 88 (61%) | 107 (92%) |
| Radioactive iodine treatment | 12 (14%) | 21 (14%) | Not available |
| Surgery | 22 (26%) | 36 (25%) | Not available |
| TRAB | 46.4±132 (n=30) | 65.5±160 (n=37) | Not available |
| TPO | 136±106 (n=6) | 752±876 (n=10) | 904±899 (n=62) |
| FT4 at diagnosis | 37.7±23.7 (n=40) | 45.2±27.5 (n=74) | 12.2±6.1 (n=47) |
| FT3 at diagnosis | 17.1±11.9 (n=32) | 35.8±124 (n=51) | 17.3±33.2 (n=6) |
| TSH | Not available | Not available | 26.9±39.8 (n=86) |
| TgAB | Not available | Not available | 169±286 (n=35) |
| Non-European | n=7 | n=32 | n=7 |
| Male | n=12 | n=30 | n=12 |
| Female | n=62 | n=101 | n=84 |
| Severity: EUGOGO scale score | 1–3 (n=58) | Not available | Not available |
Notes: Data are presented as mean ± SD, unless otherwise specified.
*
Number of patients expressed as percentage of total population. Control group (n=108 [26%*]); age: 35.7±12.8 (years).
Abbreviations: TRAB, thyroid receptors antibodies; TPO, thyroid peroxides; TSH, thyroid-stimulating hormone; TgAB, thyroglobulin antibodies; EUGOGO, European Group on Graves’ Orbitopathy; FT4, Free T4; FT3, Free T3.